BPG is committed to discovery and dissemination of knowledge
Featured Articles
3/26/2019 10:46:45 AM | Browse: 872 | Download: 1794
Publication Name World Journal of Clinical Oncology
Manuscript ID 42964
Country United States
Received
2018-11-08 03:27
Peer-Review Started
2018-11-10 08:22
First Decision by Editorial Office Director
2018-11-14 18:51
Return for Revision
2018-11-29 01:26
Revised
2018-12-27 21:35
Publication Fee Transferred
Second Decision by Editor
2019-01-08 12:57
Second Decision by Editor-in-Chief
Final Decision by Editorial Office Director
2019-01-09 03:56
Articles in Press
2019-01-09 03:56
Edit the Manuscript by Language Editor
Typeset the Manuscript
2019-02-23 09:13
Publish the Manuscript Online
2019-03-22 11:26
ISSN 2218-4333 (online)
Open Access This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
Copyright © The Author(s) 2019. Published by Baishideng Publishing Group Inc. All rights reserved.
Article Reprints For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
Permissions For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
Publisher Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
Website http://www.wjgnet.com
Category Oncology
Manuscript Type Clinical Trials Study
Article Title Evaluation of a locked nucleic acid form of antisense oligo targeting HIF-1α in advanced hepatocellular carcinoma
Manuscript Source Unsolicited Manuscript
All Author List Jennifer Wu, Merly Contratto, Krishna P Shanbhogue, Gulam A Manji, Bert H O'Neil, Anne Noonan, Robert Tudor and Ray Lee
Funding Agency and Grant Number
Corresponding Author Jennifer Wu, MD, Associate Professor, Attending Doctor, Division of Hematology and Oncology, Perlmutter Cancer Center, New York University School of Medicine, 462 First Ave, BCD556, New York, NY 10016, United States. jennifer.wu@nyumc.org
Key Words Hepatocellular carcinoma; Hypoxia-inducible factor 1α; RO7070179, Super-responder; Dynamic contrast-enhanced-magnetic resonance imaging
Core Tip Overexpression of hypoxia-inducible factor 1α (HIF-1α) correlates with poor prognosis in hepatocellular carcinoma (HCC) patients. HIF-1a inhibitor decreases HIF-1a mRNA and its downstream targets, it could be a potential treatment in HCC.
Publish Date 2019-03-22 11:26
Citation Wu J, Contratto M, Shanbhogue KP, Manji GA, O’Neil BH, Noonan A, Tudor R, Lee R. Evaluation of a locked nucleic acid form of antisense oligo targeting HIF-1α in advanced hepatocellular carcinoma. World J Clin Oncol 2019; 10(3): 149-160
URL https://www.wjgnet.com/2218-4333/full/v10/i3/149.htm
DOI https://dx.doi.org/10.5306/wjco.v10.i3.149
Full Article (PDF) WJCO-10-149.pdf
Full Article (Word) WJCO-10-149.docx